THE HUMAN–HOOKWORM ASSEMBLAGE: CONTINGENCY AND THE PRACTICE OF HELMINTHIC THERAPY

Through a qualitative analysis of the use of intestinal parasites for treating immune system disorders, this research illustrates how contingency emerges in the context of the human relationship to hookworms. The affect of the human–nonhuman relationship is an important part of understanding the direction of evolutionary medicine today, and has implications for the politics of biological health innovations. The shift from the bad parasite to a parasite that at least sometimes heals, discursively and materially, has opened new spaces for patients to change the way they relate to medical knowledge, medical professionals, and pharmaceutical companies. Hookworms are banned by the FDA, which sets the scene for lively, but sometimes rebellious, hybridity between host and parasite. Underground and do-it-yourself hookworm therapy cultures have sprung up in around the site of the gut. I argue that not only is material hookworm affect as important as human discourses in negotiating the rapidly advancing field of biome reconstruction, but it also plays a role in how that biome reconstruction takes place, conventionally or otherwise

Extensive homologies between lectins from non-leguminous plants

AbstractSequence studies were performed on lectins from two non-leguminous plants: rice and nettle. Extensive homologies were found between these two proteins and wheat germ agglutinin in support of the conservation of lectin sequences among non-leguminous plants. The number and positions of the cysteine residues were particularly well conserved suggesting a similar folding of the polypeptide chains

Core as a Novel Viral Target for Hepatitis C Drugs

Hepatitis C virus (HCV) infects over 130 million people worldwide and is a major cause of liver disease. No vaccine is available. Novel specific drugs for HCV are urgently required, since the standard-of-care treatment of pegylated interferon combined with ribavirin is poorly tolerated and cures less than half of the treated patients. Promising, effective direct-acting drugs currently in the clinic have been described for three of the ten potential HCV target proteins: NS3/NS4A protease, NS5B polymerase and NS5A, a regulatory phosphoprotein. We here present core, the viral capsid protein, as another attractive, non-enzymatic target, against which a new class of anti-HCV drugs can be raised. Core plays a major role in the virion’s formation, and interacts with several cellular proteins, some of which are involved in host defense mechanisms against the virus. This most conserved of all HCV proteins requires oligomerization to function as the organizer of viral particle assembly. Using core dimerization as the basis of transfer-of-energy screening assays, peptides and small molecules were identified which not only inhibit core-core interaction, but also block viral production in cell culture. Initial chemical optimization resulted in compounds active in single digit micromolar concentrations. Core inhibitors could be used in combination with other HCV drugs in order to provide novel treatments of Hepatitis C